Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus
1 other identifier
interventional
100
1 country
1
Brief Summary
The aim of the present study is to investigate the influence of systemic exercise, rosiglitazone administration and combined pharmaceutical and lifestyle intervention on cardiovascular risk factors
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_4
Started Jan 2005
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2005
CompletedFirst Submitted
Initial submission to the registry
March 22, 2006
CompletedFirst Posted
Study publicly available on registry
March 23, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2006
CompletedApril 4, 2007
April 1, 2007
March 22, 2006
April 3, 2007
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Cardiovascular risk factors alterations
Interventions
Eligibility Criteria
You may qualify if:
- Type II diabetes mellitus
- Poor glycemic control
You may not qualify if:
- Heart failure
- Renal disease
- Liver disease
- Cardiovascular event
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Aristotle University Of Thessalonikilead
- University of Athenscollaborator
Study Sites (1)
AHEPA University Hospital of Thessaloniki
Thessaloniki, Thessaloniki, 54454, Greece
Related Publications (5)
Kadoglou NPE, Korakas E, Lampropoulos S, Maratou E, Kassimis G, Patsourakos N, Plotas P, Moutsatsou P, Lambadiari V. Plasma nesfatin-1 and DDP-4 levels in patients with coronary artery disease: Kozani study. Cardiovasc Diabetol. 2021 Aug 13;20(1):166. doi: 10.1186/s12933-021-01355-x.
PMID: 34389003DERIVEDKadoglou NP, Vrabas IS, Kapelouzou A, Angelopoulou N. The association of physical activity with novel adipokines in patients with type 2 diabetes. Eur J Intern Med. 2012 Mar;23(2):137-42. doi: 10.1016/j.ejim.2011.10.020. Epub 2011 Nov 29.
PMID: 22284243DERIVEDKadoglou NP, Vrabas IS, Sailer N, Kapelouzou A, Fotiadis G, Noussios G, Karayannacos PE, Angelopoulou N. Exercise ameliorates serum MMP-9 and TIMP-2 levels in patients with type 2 diabetes. Diabetes Metab. 2010 Apr;36(2):144-51. doi: 10.1016/j.diabet.2009.11.004. Epub 2010 Feb 9.
PMID: 20149706DERIVEDKadoglou NP, Iliadis F, Angelopoulou N, Sailer N, Fotiadis G, Voliotis K, Vitta I, Liapis CD, Alevizos M. Cardiorespiratory capacity is associated with favourable cardiovascular risk profile in patients with Type 2 diabetes. J Diabetes Complications. 2009 May-Jun;23(3):160-6. doi: 10.1016/j.jdiacomp.2007.12.008. Epub 2008 Apr 16.
PMID: 18413173DERIVEDKadoglou NP, Iliadis F, Liapis CD, Perrea D, Angelopoulou N, Alevizos M. Beneficial effects of combined treatment with rosiglitazone and exercise on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care. 2007 Sep;30(9):2242-4. doi: 10.2337/dc07-0341. Epub 2007 Jun 22. No abstract available.
PMID: 17586747DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Christos Liapis, PhD,MD
University of Athens,Greece
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
March 22, 2006
First Posted
March 23, 2006
Study Start
January 1, 2005
Study Completion
October 1, 2006
Last Updated
April 4, 2007
Record last verified: 2007-04